Norges Bank’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Norges Bank’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,000	Closed	-$751K	–	2191
2018 Q1	$751K	Hold	40,000	–	–	﹤0.01%	2078
2017 Q4	$726K	Hold	40,000	–	–	﹤0.01%	2082
2017 Q3	$890K	Buy	+40,000	New	+$878K	﹤0.01%	2074

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank's SNNA Position: Q2 2018 in Review

Norges Bank sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2018, closing a stake of 40,000 shares — an estimated $751K sold.

Norges Bank first reported a position in SNNA in Q3 2017 and held it in 3 quarters. The position peaked at $890K in Q3 2017. 53 funds tracked by Wall St. Rank hold SNNA as of Q2 2018.

Norges Bank reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Norges Bank sold 40,000 Sienna Biopharmaceuticals, Inc. shares in Q2 2018, an estimated $751K.
Norges Bank first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
Norges Bank's Sienna Biopharmaceuticals, Inc. position peaked at $890K in Q3 2017.
53 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2018.

Based on Norges Bank's 13F filing for Q2 2018, filed 23 Jul 2018.